glp-1 drugs news today Americans are taking weight-loss in record numbers glp-1 obesity drugs news today

doi: 10.1172/jci.insight.133429 [DOI] [PMC free article] [PubMed] [Google Scholar] 146

These preclinical insights have been validated in large-scale clinical trials.The FLOW trial (n = 3,533) showed that once-weekly subcutaneous administration of semaglutide (1.0 mg) significantly reduced the risk of a renal composite endpointincluding 50% decline in eGFR, renal failure, or cardiovascular deathby 24% in patients with T2DM and chronic kidney disease (CKD) (HR = 0.76, 95% CI: 0.660.88

Informing the development of antipsychotic-induced weight gain management guidance: patient experiences and preferences a qualitative descriptive study

It may support weight loss of approximately 23 kg beyond diet alone but requires adherence to a low-fat diet to minimise gastrointestinal side effects